EUVIMEDEUVIMED entdecken
Crossref

TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor

Qi Ouyang, Shengye Tian, Hong Jiang, Moyong Li, Yuteng Zeng, Linhui Zhao, Fang Zhou, Shuanglin Xiang, Xiang Hu

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-11 · 1872 (8) · 168368

DOI: 10.1016/j.bbadis.2026.168368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-11. Verfasst von Qi Ouyang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, …. Hauptthemen laut MEDLINE: Glucosides, Colitis, Ulcerative, Phenols, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The absence of known inhibitors for TNFAIP1, a TNF-α-induced protein, has limited its exploration as a therapeutic target for ulcerative colitis (UC). This study aimed to validate TNFAIP1's pathogenic role in UC and to identify the first direct TNFAIP1-targeting compound from natural compounds. METHODS: We integrated bioinformatics analysis, DSS-induced colitis models in Tnfaip1-knockout mice, and virtual screening to identify Salidroside as a potential TNFAIP1-targeting compound. Cellular thermal shift and ubiquitination assays confirmed its direct interaction with TNFAIP1 and its effect on protein stability. Oral administration of Salidroside ameliorated colitis in wild-type mice, phenocopying the protective effect of Tnfaip1 deficiency. RESULTS: TNFAIP1 was significantly upregulated in UC patients and colitic mice. Tnfaip1-knockout conferred profound resistance to colitis, mechanistically linked to the suppression of the IKK/IκB/NF-κB pathway, modulation of CREB signaling, and restoration of a beneficial gut microbiota. Based on this target validation, virtual screening identified Salidroside as a top candidate. Crucially, Salidroside administration in wild-type mice phenocopied the protective effects of genetic knockout, alleviating disease severity and downregulating the TNFAIP1-driven inflammatory network. CETSA confirmed a direct physical interaction between Salidroside and TNFAIP1. CONCLUSION: This study validates TNFAIP1 as a key pathogenic driver of UC and identifies Salidroside as a first-in-class direct TNFAIP1-targeting compound with therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesColitis, UlcerativePhenolsAdaptor Proteins, Signal TransducingAnimalsHumansMiceMice, KnockoutGastrointestinal MicrobiomeMaleDisease Models, AnimalSignal TransductionNF-kappa BDextran SulfateMice, Inbred C57BL

Stichwörter der Autor:innen

Gut microbiotaSalidrosideTNFAIP1UC

Substanzen

GlucosidesrhodiolosidePhenolsTNFAIP1 protein, humanAdaptor Proteins, Signal TransducingNF-kappa BDextran Sulfate

Autor:innen und Institutionen

  • The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China.
  • Engineering Research Center for Antibodies from Experimental Animals of Hunan Province, College of Life Sciences, Hunan Normal University, Changsha, China.
  • Engineering Research Center for Antibodies from Experimental Animals of Hunan Province, College of Life Sciences, Hunan Normal University, Changsha, China. Electronic address: xshlin@hunnu.edu.cn.
  • The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China. Electronic address: huxiang@hunnu.edu.cn.

Zitieren

APA

Ouyang, Q., Tian, S., Jiang, H., Li, M., Zeng, Y., Zhao, L., Zhou, F., Xiang, S., & Hu, X. (2026). TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(8), 168368. https://doi.org/10.1016/j.bbadis.2026.168368

Vancouver

Ouyang Q, Tian S, Jiang H, Li M, Zeng Y, Zhao L, et al. TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(8):168368. doi:10.1016/j.bbadis.2026.168368

BibTeX
@article{Ouyang2026,
  author = {Ouyang, Qi and Tian, Shengye and Jiang, Hong and Li, Moyong and Zeng, Yuteng and Zhao, Linhui and Zhou, Fang and Xiang, Shuanglin and Hu, Xiang},
  title = {TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor},
  journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
  year = {2026},
  volume = {1872},
  number = {8},
  pages = {168368},
  doi = {10.1016/j.bbadis.2026.168368}
}
Kostenlos starten →